Osteosarcoma and other tumors of bone.
Steady progress has been made in the identification of genetic alterations and prognostic factors in osteosarcoma. Imaging studies continue to be employed not only for preoperative staging, but to quantify factors such as tumor bulk and tumor response to neoadjuvant chemotherapy. Although there have been no major refinements of local or systemic therapy, continuing research into novel agents (eg, liposomal muramyl, tripeptide phosphatidylethanolamine, and antisense oligonucleotides to insulin-like growth factor receptors) hold promise for new therapies for this disease in the future.
Mertens
W C
WC
London Regional Cancer Centre, Ontario, Canada.
Bramwell
V
V
D000293:Adolescent; D000328:Adult; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D001859:Bone Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000473:pathology / Q000628:therapy; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D005260:Female; D016147:Genes, Tumor Suppressor; D014943:Global Health; D006801:Humans; D015994:Incidence; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009857:Oncogenes; D012516:Osteosarcoma / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D012513:Sarcoma, Experimental / Q000473:pathology; D016896:Treatment Outcome
D014408:Biomarkers, Tumor